Teva share price logo

Teva

NYSE: TEVA

Large Cap

$39.19

-1.03

(-2.56%)

as on

Teva Stock Performance

as on September 26, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $38.93
    $40.18
    downward going graph

    0.66%

    Downside

    2.53%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $18.27
    $40.79
    downward going graph

    53.38%

    Downside

    4.08%

    Upside

    downward going graph

Teva share price movements today

Previous Close
$40.22
Open
$40.17
Volume
3.1M
Market Cap
$42.7B
Day's Low - High
$38.93 - $40.18
52 Week Low - High
$18.27 - $40.79

Teva Historical Returns

1 Month Return
+ 3.35 %
3 Month Return
+ 18.01 %
1 Year Return
+ 113.69 %
3 Year Return
+ 283.46 %
5 Year Return
+ 337.88 %

Teva Stock Fundamentals & Key Indicators

Check Teva market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$42.7B

EPS (TTM)

0.63

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.72%

PE Ratio (TTM)

62.69

Industry PE ratio

16.45

PEG Ratio

0.11398987012987015

EBITDA

3.1B

Revenue (TTM)

17.4B

Profit Margin

52.46%

Return On Equity TTM

9.18%

Teva Stock Valuation

Track how Teva P/E has moved over time to understand its valuation trends.

Teva in the last 5 years

  • Overview

  • Trends

Lowest (-21.16x)

December 31, 2023

Industry (16.45x)

December 31, 2025

Today (25.74x)

December 31, 2025

Highest (25.74x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 25.74x

Teva vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Teva with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$42.7B337.88%62.6952.46%0.00%
Buy$20.3B143.7%15.6286.14%0.00%
Buy$19.7B33.26%-48.3934.83%2.80%
Buy$39.9BNA19.0165.57%1.36%
Buy$30.1B-65.3%11.5670.87%2.92%

Stock Returns calculator for Teva Stock including INR - Dollar returns

The Teva stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Teva investment value today

Current value as on today

₹2,30,828

Returns

₹1,30,828

(+130.83%)

Returns from Teva Stock

₹1,13,686 (+113.69%)

Dollar Impact

₹17,142 (+17.14%)

Analyst Recommendation on Teva Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Teva. Average target price of $44

Teva Share Price Target

Get share price movements and forecasts by analysts on Teva.

What analysts predicted

10.93%UPSIDE

Target Price

$44

Current Price

$39.19

Analyzed by

3 Analysts

High

$43

Target

$44.00

Low

$42

Teva target price $44, a slight upside of 10.93% compared to current price of $39.19. According to 3 analysts rating.

Indian Investors' Interest in Teva Stock

Search interest for Teva Stock has increased by 66% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:66% versus previous 30 day period

Teva Quarterly Profit & Loss

All numbers in Millions USD

Jun 2025
Jun 2025
Sep 2025
Sep 2025
Dec 2025
Dec 2025
Mar 2026
Mar 2026
Jun 2026
Jun 2026
Total Revenue
4,176
4,176
4,480
4,480
4,711
4,808
3,981
3,971
4,142
4,142
Gross Profit
2,102
2,102
2,304
2,304
2,656
2,699
1,972
1,972
2,153
2,153
Operating Income
455
455
882
882
300
1,294
652
652
149
-231
EBITDA
657
657
1,104
1,106
632
571
877
996
-19
408
Interest Expense
203
203
209
209
292
224
201
215
200
221
Depreciation
251
251
249
249
260
265
239
238
241
241
Income Before Tax
204
203
648
648
91
92
436
436
-455
-455
Income Tax Expense
-78
-78
214
214
-390
-397
67
66
121
121
Net Income
282
282
433
433
480
489
369
370
-576
-576
Net Profit Margin
50.34%
50.34%
51.43%
51.43%
56.38%
56.15%
49.54%
49.65%
51.98%
51.98%

Teva Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2021
Dec 2022
Dec 2022
Dec 2023
Dec 2023
Dec 2024
Dec 2024
Dec 2025
Dec 2025
Total Revenue
15,878
15,878
14,925
14,925
15,845
15,846
16,544
16,544
17,257
18,681
Gross Profit
7,594
7,594
6,973
6,973
7,645
7,646
8,063
8,063
8,938
9,631
Operating Income
1,716
1,716
-2,197
-2,099
433
433
-303
-303
2,157
4,277
EBITDA
4,409
2,879
-925
-925
1,558
1,558
4,431
777
3,141
3,420
Interest Expense
891
1,058
930
966
1,029
1,029
941
1,002
916
1,011
Depreciation
1,330
1,330
1,308
1,308
1,153
1,153
1,059
1,059
1,002
1,084
Income Before Tax
667
658
-3,142
-3,065
-622
-622
-1,283
-1,284
1,238
1,340
Income Tax Expense
211
211
-643
-638
-7
-7
676
676
-180
-194
Net Income
417
417
-2,446
-2,353
-559
-559
-1,639
-1,639
1,410
1,527
Net Profit Margin
47.83%
47.83%
46.72%
46.72%
48.25%
48.25%
48.74%
48.74%
51.79%
51.56%

Teva Quarterly Cash Flow

All numbers in Millions USD

Jun 2025
Jun 2025
Sep 2025
Sep 2025
Dec 2025
Dec 2025
Mar 2026
Mar 2026
Jun 2026
Jun 2026
Net Income
283
283
434
434
481
489
369
370
-575
-568
Operating Cash Flow
227
227
369
369
1,158
1,529
-40
313
411
721
Investing Cash Flow
236
236
135
135
165
-118
229
-124
-491
-809
Financing Cash Flow
6
6
-453
-453
40
88
13
12
-1
-1
Change in Cash
464
464
42
42
1,353
1,272
185
153
-86
-307

Teva Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2021
Dec 2022
Dec 2022
Dec 2023
Dec 2023
Dec 2024
Dec 2024
Dec 2025
Dec 2025
Net Income
456
456
-2,499
-2,406
-615
-559
-1,959
-1,959
1,418
1,527
Operating Cash Flow
798
798
1,590
1,590
1,368
1,368
1,247
1,247
1,649
3,099
Investing Cash Flow
1,523
1,523
656
656
968
968
792
792
737
-557
Financing Cash Flow
-2,172
-2,172
-1,487
-1,487
-1,913
-1,913
-1,791
-1,791
-2,151
-2,287
Change in Cash
21
21
636
636
393
393
73
73
256
-216

Mutual Funds that own Teva Stock

Check out the Mutual Funds with significant holdings in Teva.

Funds
Holdings
Shares Held
INVESTMENT MANAGERS SERIES TRUST
1.150253%
13403860
Fidelity Investment Trust
0.657156%
7657817
Fidelity Contrafund
0.636122%
7412711
New Economy Fund
0.424198%
4943168
Fidelity Concord Street Trust
0.390275%
4547862

Global Institutional Holdings in Teva

Funds
Holdings
iShares
2.9%
INVESTMENT MANAGERS SERIES TRUST
1.15%
David Gerald Greenspan
0.68%
Fidelity Investment Trust
0.66%
Fidelity Contrafund
0.64%

Teva News & Key Events

  • img

    Today's Timeline - 23 September

    Wed, 05:32 PM

    -

    Teva secures investment-grade ratings, enhancing financial flexibility for innovative product launches and debt reduction.

    Wed, 07:20 PM

    -

    Oppenheimer initiates coverage of Teva with an Outperform rating and $50 price target, citing growth potential.

Insights on Teva

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Teva Pharmaceutical Industries Limited has shown positive revenue growth over the last two quarters. Revenue increased from $3.98 billion to $4.14 billion, reflecting an average growth rate of 3.9% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, TEVA stock has moved up by 113.7%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, TEVA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, TEVA has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Teva Pharmaceutical Industries Limited has experienced a decline in net profit over the last three quarters. The net profit decreased from $480.0 million to -$576.0 million, indicating a significant downturn. On average, the profit decreased by 139.6% each quarter.

About Teva

Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
OrganisationTeva
Headquarters124 Dvora Hanevi’a Street, Tel Aviv, TA, 6944020, IL
IndustryDrug Manufacturers - Specialty & Generic
CEORichard D. Francis
E-voting on sharesClick here to vote

Key Management of Teva

Name

Title

Mr. Richard D. Francis

President, CEO & Director

Ms. Christine Fox

Executive VP of US Commercial & Head of Innovative Franchise

Mr. Evan Lippman M.B.A.

Executive Vice President of Business Development

Kathleen Veit

Senior Vice President, Global Compliance & Ethics Officer

Mr. Eliyahu Sharon Kalif

Executive VP & CFO

Dr. Eric A. Hughes M.D., Ph.D.

Executive VP of Global R&D and Chief Medical Officer

Mr. Matthew Shields

Executive Vice President of Global Operations

Mr. Amir Weiss

Senior VP & Chief Accounting Officer

Mr. Christopher J. Stevo CFA

Senior Vice President of Investor Relations & Competitive Intelligence

Mr. Brian Savage

Interim Chief Legal Officer

FAQs

What is Teva share price today?

Teva share price today is $39.19 as on at the close of the market. Teva share today touched a day high of $40.18 and a low of $38.93.

What is the 52 week high and 52 week low for Teva share?

Teva share touched a 52 week high of $40.79 on and a 52 week low of $18.27 on . Teva stock price today i.e. is closed at $39.19,which is 3.92% down from its 52 week high and 114.50% up from its 52 week low.

What is Teva's market capitalisation today?

Teva market capitalisation is $0.04T as on .

How to invest in Teva Stock (TEVA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Teva on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Teva Shares that will get you 0.0383 shares as per Teva share price of $39.19 per share as on September 26, 2026 at 8:46 am IST.

What is the minimum amount required to buy Teva Stock (TEVA) from India?

Indian investors can start investing in Teva (TEVA) shares with as little as ₹95.819999694824 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.20 in Teva stock (as per the Rupee-Dollar exchange rate as on ). Based on Teva share’s latest price of $39.19 as on September 26, 2026 at 8:46 am IST, you will get 0.2552 shares of Teva. Learn more about fractional shares .

What are the returns that Teva has given to Indian investors in the last 5 years?

Teva stock has given 337.88% share price returns and 29.98% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?